Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05729373 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 434
- Enrollment target
NCT05729373: Completed Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT05729373 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 434 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (226% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05729373, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 434 participants
- Enrollment target
Study Summary
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Primary Outcome
The HAM-A scale consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point (0-4) scale, with higher scores indicating greater severity.
Interventions
- DRUG Placebo
- DRUG SEP-363856
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 434 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 2 |
What the finished NCT05729373 record still lists
NCT05729373 is an interventional study that assigns participants to a tested intervention. The registered 434 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (226% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05729373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05729373 about?
NCT05729373 is a clinical study titled "A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder". A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and ap...
What is the current status of trial NCT05729373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 434 participants. The study started on 2023-03-08. Estimated completion is 2025-09-26.
What interventions are being tested in trial NCT05729373?
The interventions under investigation include: Placebo (DRUG), SEP-363856 (DRUG).
Who is sponsoring clinical trial NCT05729373?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05729373's enrollment target sits among peer trials
434 90th of 2000 higher than 1,911 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04743245 · 434 participants · NA
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
- NCT06471920 · 434 participants · NA
Improving Health for Patients With Chronic LBP in Rural Communities Through Telerehabilitation
- NCT07094113 · 434 participants · Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- NCT05563220 · 435 participants · Phase 1
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI